Compared to the untreated and non‐target (NC) controls, all three MAS1 saRNAs delivered by AD significantly enhanced the MAS1 protein (Figure 2i,j) and transcript (Figure S6a,b, Supporting Information) levels in both breast cancer cell lines. This evidence concerns the gene MAS1 and breast carcinoma.